Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen IncfiledCriticalAmgen Inc
Publication of UY29409A1publicationCriticalpatent/UY29409A1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
La presente invención comprende una nueva clase de compuestos útiles para la profilaxis y tratamiento de enfermedades mediadas por la quinasa proteica, incluyendo condiciones de inflamación y relacionadas. Los compuestos tienen una Fómula general I donde A1, A2, B, R2, R3, y R4, son según se definen aquí. La invención comprende también composiciones farmacéuticas que incluyen uno o más compuestos de la Fórmula I, los usos de dichos compuestos y composiciones para el tratamiento de las enfermedades mediadas por las quinasas, incluyendo artritis reumatoide, soriasis y otras afecciones inflamatorias, así como productos intermedios y procesos útiles para la preparacion de los compuestos de Fórmula I.The present invention comprises a new class of compounds useful for the prophylaxis and treatment of diseases mediated by protein kinase, including inflammation and related conditions. The compounds have a general formula I where A1, A2, B, R2, R3, and R4, are as defined herein. The invention also comprises pharmaceutical compositions that include one or more compounds of Formula I, the uses of said compounds and compositions for the treatment of kinase-mediated diseases, including rheumatoid arthritis, psoriasis and other inflammatory conditions, as well as intermediates and Useful processes for the preparation of the compounds of Formula I.
UY29409A2005-03-032006-03-03
COMPOUNDS OF FTALAZINE, AZA- AND DIAZA-FTALAZINA AND METHODS OF USE
UY29409A1
(en)
DERIVED FROM THE 1, 3, 5-TRIAZINA-2, 4-DIAMINAS-6-SUBSTITUTED-N-SUBSTITUTED AND PHARMACEUTICALLY ACCEPTABLE SALTS OF THE SAME, COMPOSITIONS AND APPLICATIONS.